The therapeutic effect of anti-CD52 treatment in murine experimental autoimmune encephalomyelitis is associated with altered IL-33 and ST2 expression levels

Mark Barbour, Rachel Wood, Shehla U Hridi, Chelsey Wilson, Grant McKay, Trevor J Bushell, Hui-Rong Jiang

Research output: Contribution to journalArticle

3 Citations (Scopus)
24 Downloads (Pure)


Experimental autoimmune encephalomyelitis (EAE) mice were administered with murine anti-CD52 antibody to investigate its therapeutic effect and whether the treatment modulates IL-33 and ST2 expression. EAE severity and central nervous system (CNS) inflammation were reduced following the treatment, which was accompanied by peripheral T and B lymphocyte depletion and reduced production of various cytokines including IL-33, while sST2 was increased. In spinal cords of EAE mice, while the number of IL-33+ cells remained unchanged, the extracellular level of IL-33 protein was significantly reduced in anti-CD52 antibody treated mice compared with controls. Furthermore the number of ST2+ cells in the spinal cord of treated EAE mice was downregulated due to decreased inflammation and immune cell infiltration in the CNS. These results suggest that treatment with anti-CD52 antibody differentially alters expression of IL-33 and ST2, both systemically and within the CNS, which may indicateIL-33/ST2 axis is involved in the action of the antibody in inhibiting EAE.
Original languageEnglish
Pages (from-to)1-33
Number of pages33
JournalJournal of Neuroimmunology
Early online date24 Feb 2018
Publication statusE-pub ahead of print - 24 Feb 2018


  • multiple sclerosis
  • experimental autoimmune encephalomyelitis
  • CD52
  • IL-33
  • ST2

Cite this